title: Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.
abstract: The aim of this study was to evaluate the long-term effect of 2 years of adjuvant tamoxifen compared with no systemic treatment (control) in premenopausal patients with breast cancer over different time periods through long-term (> 25 years) follow-up.
  
  
  
  Premenopausal patients with primary breast cancer (N = 564) were randomly assigned to 2 years of tamoxifen (n = 276) or no systemic treatment (n = 288). Data regarding date and cause of death were obtained from the Swedish Cause of Death Register. End points were cumulative mortality (CM) and cumulative breast cancer-related mortality (CBCM). The median follow-up for the 250 patients still alive in April 2014 was 26.3 years (range, 22.7 to 29.7 years).
  
  
  
  In patients with estrogen receptor-positive tumors (n = 362), tamoxifen was associated with a marginal reduction in CM (hazard ratio [HR], 0.77; 95% CI, 0.58 to 1.03; P = .075) and a significant reduction in CBCM (HR, 0.73; 95% CI, 0.53 to 0.99; P = .046). The effect seemed to vary over time (CM years 0 to 5: HR, 1.05; 95% CI, 0.64 to 1.73; years > 5 to 15: HR, 0.58; 95% CI, 0.37 to 0.91; and after 15 years: HR, 0.82; 95% CI, 0.48 to 1.42; CBCM years 0 to 5: HR, 1.09; 95% CI, 0.65 to 1.82; years > 5 to 15: HR, 0.53; 95% CI, 0.33 to 0.86; and after 15 years: HR, 0.72; 95% CI, 0.36 to 1.44).
  
  
  
  Two years of adjuvant tamoxifen resulted in a long-term survival benefit in premenopausal patients with estrogen receptor-positive primary breast cancer.
authors.affiliation: Maria Ekholm, Pär-Ola Bendahl, Mårten Fernö, and Lisa Rydén, Lund University, Lund; Maria Ekholm, Ryhov County Hospital, Jönköping; and Bo Nordenskjöld and Olle Stål, Linköping University, Linköping, Sweden. maria.ekholm@med.lu.se.
authors.forename: Maria
authors.initials: M
authors.lastname: Ekholm
authors.affiliation: Maria Ekholm, Pär-Ola Bendahl, Mårten Fernö, and Lisa Rydén, Lund University, Lund; Maria Ekholm, Ryhov County Hospital, Jönköping; and Bo Nordenskjöld and Olle Stål, Linköping University, Linköping, Sweden.
authors.forename: Pär-Ola
authors.initials: PO
authors.lastname: Bendahl
authors.affiliation: Maria Ekholm, Pär-Ola Bendahl, Mårten Fernö, and Lisa Rydén, Lund University, Lund; Maria Ekholm, Ryhov County Hospital, Jönköping; and Bo Nordenskjöld and Olle Stål, Linköping University, Linköping, Sweden.
authors.forename: Mårten
authors.initials: M
authors.lastname: Fernö
authors.affiliation: Maria Ekholm, Pär-Ola Bendahl, Mårten Fernö, and Lisa Rydén, Lund University, Lund; Maria Ekholm, Ryhov County Hospital, Jönköping; and Bo Nordenskjöld and Olle Stål, Linköping University, Linköping, Sweden.
authors.forename: Bo
authors.initials: B
authors.lastname: Nordenskjöld
authors.affiliation: Maria Ekholm, Pär-Ola Bendahl, Mårten Fernö, and Lisa Rydén, Lund University, Lund; Maria Ekholm, Ryhov County Hospital, Jönköping; and Bo Nordenskjöld and Olle Stål, Linköping University, Linköping, Sweden.
authors.forename: Olle
authors.initials: O
authors.lastname: Stål
authors.affiliation: Maria Ekholm, Pär-Ola Bendahl, Mårten Fernö, and Lisa Rydén, Lund University, Lund; Maria Ekholm, Ryhov County Hospital, Jönköping; and Bo Nordenskjöld and Olle Stål, Linköping University, Linköping, Sweden.
authors.forename: Lisa
authors.initials: L
authors.lastname: Rydén
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D011960:Receptors, Estrogen; D013629:Tamoxifen